ST6GalNAcII mediates tumor invasion through PI3K/Akt/NF-κB signaling pathway in follicular thyroid carcinoma

Miao,Xiaolong; Zhao,Yongfu

doi:10.3892/or.2016.4590

ST6GalNAcII mediates tumor invasion through PI3K/Akt/NF-κB signaling pathway in follicular thyroid carcinoma

Authors:
- Xiaolong Miao
- Yongfu Zhao
View Affiliations

Affiliations: Department of General Surgery, Dalian Medical University, Liaoning, P.R. China, Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Liaoning, P.R. China
Published online on: January 22, 2016 https://doi.org/10.3892/or.2016.4590
Pages: 2131-2140

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Altered sialylation, closely associated with tumor progression and metastasis, has been implicated in human thyroid carcinoma. The present study investigated the alteration in expression of ST6GalNAcII involved in invasion and to clarify the possible mechanism of ST6GalNAcII in the metastasis process in human follicular thyroid carcinoma cell lines. Using real-time PCR, western blot and IHC analysis, ST6GalNAcII differed in three follicular thyroid cancer cell lines (FTC133, primary and FTC238, lung metastasis). It also showed differential expression in follicular thyroid carcinoma and tissue specimens. In addition, we analyzed the PI3K/Akt signaling pathway. The altered expression of ST6GalNAcII corresponded to changed invasive phenotype of FTC-238 and FTC-133 cells in vitro and in vivo. Further studies showed that regulating ST6GalNAcII expression markedly modulated the activity of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. Targeting the PI3K/Akt pathway by its specific inhibitor LY294002, or by Akt small interfering RNA (siRNA) resulted in reduced capacity in invasion of FTC-238. In conclusion, taken together, our results imply that ST6GalNAcII activated the invasion in follicular thyroid cancer cells through regulating the activity of PI3K/Akt pathway.

View Figures

View References

1	Dall'Olio F and Chiricolo M: Sialyltransferases in cancer. Glycoconj J. 18:841–850. 2001. View Article : Google Scholar
2	Harvey BE, Toth CA, Wagner HE, Steele GD Jr and Thomas P: Sialyltransferase activity and hepatic tumor growth in a nude mouse model of colorectal cancer metastases. Cancer Res. 52:1775–1779. 1992.PubMed/NCBI
3	Majuri ML, Niemelä R, Tiisala S, Renkonen O and Renkonen R: Expression and function of alpha 2,3-sialyl- and alpha 1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines: Role in synthesis of E-selectin counter-receptors. Int J Cancer. 63:551–559. 1995. View Article : Google Scholar : PubMed/NCBI
4	Yogeeswaran G and Salk PL: Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science. 212:1514–1516. 1981. View Article : Google Scholar : PubMed/NCBI
5	Dennis J, Waller C, Timpl R and Schirrmacher V: Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin. Nature. 300:274–276. 1982. View Article : Google Scholar : PubMed/NCBI
6	Ohtsubo K and Marth JD: Glycosylation in cellular mechanisms of health and disease. Cell. 126:855–867. 2006. View Article : Google Scholar : PubMed/NCBI
7	Kim YJ, Kim KS, Kim SH, Kim CH, Ko JH, Choe IS, Tsuji S and Lee YC: Molecular cloning and expression of human Gal beta 1,3GalNAc alpha 2,3-sialytransferase (hST3Gal II). Biochem Biophys Res Commun. 228:324–327. 1996. View Article : Google Scholar : PubMed/NCBI
8	Harduin-Lepers A, Mollicone R, Delannoy P and Oriol R: The animal sialyltransferases and sialyltransferase-related genes: A phylogenetic approach. Glycobiology. 15:805–817. 2005. View Article : Google Scholar : PubMed/NCBI
9	Takashima S, Tsuji S and Tsujimoto M: Characterization of the second type of human beta-galactoside alpha 2,6-sialyl-transferase (ST6Gal II), which sialylates Galbeta 1,4GlcNAc structures on oligosaccharides preferentially. Genomic analysis of human sialyltransferase genes. J Biol Chem. 277:45719–45728. 2002. View Article : Google Scholar : PubMed/NCBI
10	Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart AS, Hanisch FG, Delannoy P and Le Bourhis X: ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology. 16:54–64. 2006. View Article : Google Scholar
11	Ding JX, Xu LX, Zhu L, Lv JC, Zhao MH, Zhang H and Wang HY: Activity of α2,6-sialyltransferase and its gene expression in peripheral B lymphocytes in patients with IgA nephropathy. Scand J Immunol. 69:174–180. 2009. View Article : Google Scholar : PubMed/NCBI
12	Xu LX and Zhao MH: Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int. 68:167–172. 2005. View Article : Google Scholar : PubMed/NCBI
13	Reticker-Flynn NE and Bhatia SN: Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. Cancer Discov. 5:168–181. 2015. View Article : Google Scholar :
14	Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, et al: Genes that mediate breast cancer metastasis to the brain. Nature. 459:1005–1009. 2009. View Article : Google Scholar : PubMed/NCBI
15	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
16	Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
17	Tamburrino A, Molinolo AA, Salerno P, Chernock RD, Raffeld M, Xi L, Gutkind JS, Moley JF, Wells SA Jr and Santoro M: Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res. 18:3532–3540. 2012. View Article : Google Scholar : PubMed/NCBI
18	Xu X, Qin J and Liu W: Curcumin inhibits the invasion of thyroid cancer cells via down-regulation of PI3K/Akt signaling pathway. Gene. 546:226–232. 2014. View Article : Google Scholar : PubMed/NCBI
19	Vu-Phan D, Grachtchouk V, Yu J, Colby LA, Wicha MS and Koenig RJ: The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype. Endocr Relat Cancer. 20:725–739. 2013. View Article : Google Scholar : PubMed/NCBI
20	Milosevic Z, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J, Dzodic R, Tanic N and Bankovic J: Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res. 164:411–423. 2014. View Article : Google Scholar : PubMed/NCBI
21	Geraldo MV, Yamashita AS and Kimura ET: MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer. Oncogene. 31:1910–1922. 2012. View Article : Google Scholar
22	Soula-Rothhut M, Coissard C, Sartelet H, Boudot C, Bellon G, Martiny L and Rothhut B: The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. Exp Cell Res. 304:187–201. 2005. View Article : Google Scholar : PubMed/NCBI
23	Sawada M, Moriya S, Saito S, Shineha R, Satomi S, Yamori T, Tsuruo T, Kannagi R and Miyagi T: Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression. Int J Cancer. 97:180–185. 2002. View Article : Google Scholar : PubMed/NCBI
24	Lin S, Kemmner W, Grigull S and Schlag PM: Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp Cell Res. 276:101–110. 2002. View Article : Google Scholar : PubMed/NCBI
25	Ren D, Jia L, Li Y, Gong Y, Liu C, Zhang X, Wang N and Zhao Y: ST6GalNAcII mediates the invasive properties of breast carcinoma through PI3K/Akt/NF-κB signaling pathway. IUBMB Life. 66:300–308. 2014. View Article : Google Scholar : PubMed/NCBI
26	Zhou F, Cui C, Ge Y, Chen H, Li Q, Yang Z, Wu G, Sun S, Chen K, Gu J, et al: Alpha2,3-Sialylation regulates the stability of stem cell marker CD133. J Biochem. 148:273–280. 2010. View Article : Google Scholar : PubMed/NCBI
27	Li Z: CD133: A stem cell biomarker and beyond. Exp Hematol Oncol. 2:172013. View Article : Google Scholar : PubMed/NCBI
28	Zhao Y, Li Y, Ma H, Dong W, Zhou H, Song X, Zhang J and Jia L: Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma. Mol Cell Proteomics. 13:520–536. 2014. View Article : Google Scholar :
29	López-Morales D, Velázquez-Márquez N, Valenzuela O, Santos-López G, Reyes-Leyva J and Vallejo-Ruiz V: Enhanced sialyltransferases transcription in cervical intraepithelial neoplasia. Invest Clin. 50:45–53. 2009.PubMed/NCBI
30	Wang PH, Lee WL, Juang CM, Yang YH, Lo WH, Lai CR, Hsieh SL and Yuan CC: Altered mRNA expressions of sialyl-transferases in ovarian cancers. Gynecol Oncol. 99:631–639. 2005. View Article : Google Scholar : PubMed/NCBI